Viridian Posts $127M Q2 Loss, $982M Cash; Lumvoa Launch Underway After FDA Nod
VRDN sits 58% above its 52-week low of $13.18.
Summary
Viridian reported a $127M Q2 net loss with $982M in cash, sufficient to reach break-even. The quarter marked the U.S. launch of Lumvoa for TED, with early physician interest noted. The company also closed a $250M convertible note offering, repaid its Hercules loan, and advanced its elegrobart program toward a 2027 BLA.
Key Events · Earnings and Guidance · VRDN
-
Q2 Net Loss of $127M
Net loss widened to $127M from $101M a year ago, driven by a $35M increase in SG&A to $55M as the company built out its commercial infrastructure for the Lumvoa launch. R&D spending fell $15M to $72M as veligrotug trials wound down.
-
Cash Runway Extended to Break-Even
Cash, equivalents, and marketable securities totaled $981.5M at June 30, 2026, following $393M in gross proceeds from a May 2026 convertible note and equity offering. Management expects this to fund operations to break-even.
-
Lumvoa Launch Underway with Early Physician Interest
The FDA approved veligrotug (Lumvoa) for TED in June 2026. The company reported strong early physician interest and has established a commercial team, patient support program, and manufacturing agreement with WuXi Biologics.
-
Debt Restructured: Hercules Loan Repaid, $250M Convertible Notes Issued
Viridian repaid its $55.1M Hercules loan in May 2026, recording a $4.1M loss on extinguishment. It concurrently issued $250M of 1.75% convertible senior notes due 2032 and sold 8.46M common shares at $17.00 for $143.8M in gross proceeds.
Analysis · VRDN · Life Sciences
This is Viridian's first quarterly report since the June 2026 FDA approval of Lumvoa (veligrotug) for thyroid eye disease. The $127M net loss reflects heavy commercial launch spending, but the $982M cash position—bolstered by a $250M convertible note and $143.8M equity raise in May—extends runway to break-even. Early launch metrics show strong physician interest, a critical leading indicator for the company's first commercial product. The report also details the termination of the Hercules loan, a new WuXi manufacturing pact, and receipt of a $75M DRI milestone, all reshaping the balance sheet. With elegrobart Phase 3 data in hand and a BLA planned for early 2027, the pipeline narrative is advancing, but near-term focus remains on Lumvoa's commercial execution.
At the time of this filing, VRDN was trading at $20.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $13.18 to $34.29. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.